Clinical Trials Logo

Filter by:
NCT ID: NCT01217697 Approved for marketing - Clinical trials for Urogenital Neoplasms

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).

NCT ID: NCT01217606 Completed - Ocular Hypertension Clinical Trials

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Start date: January 2011
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

NCT ID: NCT01217320 Recruiting - Clinical trials for Juvenile Dermatomyositis

Creatine Supplementation in Pediatric Rheumatology

Start date: January 2011
Phase: N/A
Study type: Interventional

Creatine supplementation may improve strength, muscle mass, bone mass and muscle function in healthy and elderly people. The investigators speculate that creatine supplementation could have therapeutic effects in pediatric rheumatic (i.e., juvenile systemic lupus erythematosus and juvenile dermatomyositis) patients who usually present muscle weakness, muscle wasting and bone mass loss.

NCT ID: NCT01217255 Completed - Hemophilia A Clinical Trials

Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World

Start date: September 2010
Phase:
Study type: Observational

Because of high cost, persons with hemophilia in many developing countries cannot afford adequate treatment. For example, many persons with hemophilia in India and China are only rarely treated with factor replacement in response to bleeds, and as a result many have developed significant arthropathy and disability. A pilot study in China estimated the mean Hemophilia Joint Health Score (HJHS) at 13.1 (SD 9.03) suggesting that these children had highly prevalent, severe joint disease. The lack of relationship between the HJHS and treatment history suggests overall inadequate therapy. The proposed study will quantify the burden of arthropathy, physical disability, and quality of life (QoL) in boys with hemophilia in Brazil - where comprehensive treatment is just beginning to be widely available. This study will also provide an opportunity to compare these outcomes to those observed in Canada, where the dominant therapy has become life-long prophylaxis.

NCT ID: NCT01217177 Completed - Clinical trials for Locally Advanced Cervical Cancer

A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer

PHOENIX I
Start date: December 2011
Phase: Phase 1
Study type: Interventional

The cervix cancer is the second malignant neoplasia more common between women. The combined treatment involving chemotherapy and radiotherapy was defined as the standard. This study will evaluate the safety, toxicity and maximal tolerated dose (MTD) of everolimus in association with cisplatin and pelvic radiotherapy, in patients with squamous cells carcinoma of uterine cervix, in stages IIB and IIIB.

NCT ID: NCT01217164 Completed - Weight Gain Preterm Clinical Trials

Strategy to Minimize In-hospital Malnutrition in Premature Babies

SPN
Start date: October 2008
Phase: Phase 0
Study type: Interventional

Adequate nutrition is important for preventing malnutrition in the postnatal period and thus optimize growth and development of children born prematurely. To avoid malnutrition is recommended to provide nutrients necessary for a growth rate similar to the intrauterine life. For nearly one decade studying how to minimize in-hospital malnutrition in children born prematurely, especially with gestational age less than 32 weeks or with birth weight below 1,500 g, called newborn very low birth weight (VLBW). Embleton et al.demonstrated that with the current nutritional recommendations (protein between 3.0 and 3.8 g / kg / day), the VLBW had malnutrition caused by protein and calorie cumulative deficit. Poor nutrition in the neonatal period can impair growth and neuromotor and cognitive development after hospital discharge. The investigators hypothesis is that VLBW subjected to aggressive nutrition with protein-calorie high from birth until discharge, would present higher weight gain than the VLBW infants who received routine diet of service, without producing adverse effects.

NCT ID: NCT01216839 Recruiting - Clinical trials for Refractory or Relapsed RMS and Soft Tissue Sarcomas

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

Start date: March 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed Rhabdomyosarcoma and other soft tissue sarcomas

NCT ID: NCT01216826 Recruiting - Clinical trials for Refractory or Relapsed Osteosarcoma

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma

Start date: March 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed osteosarcoma. The aim response is defined as complete or partial response (according to RECIST criteria) for at least 4 weeks, or stable disease for at least 12 weeks.

NCT ID: NCT01215955 Completed - Clinical trials for Diabetes Mellitus, Type 2

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

AUTONOMY
Start date: December 2010
Phase: Phase 4
Study type: Interventional

Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants with type 2 diabetes mellitus not achieving adequate glycemic control on basal insulin.

NCT ID: NCT01215942 Terminated - Clinical trials for Rheumatoid Arthritis

An Open Label Study for Participants With Rheumatoid Arthritis

Start date: June 2011
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to help answer if LY2127399 is safe and effective during long-term treatment in participants with Rheumatoid Arthritis. This study is comprised of 2 periods: Period 1: Unblinded treatment for up to 240 weeks for participants who enroll from Study H9B-MC-BCDO (BCDO) (NCT01202760) or Study H9B-MC-BCDV (BCDV) (NCT01202773) or up to 168 weeks for participants who enroll from Study H9B-MC-BCDM (BCDM) (NCT01198002). Period 2: 48-week post-treatment follow-up